UCB reports positive trial outcomes for bimekizumab, demonstrating head-to-head superiority in joint endpoints against an approved biologic for psoriatic arthritis. This positions bimekizumab as a strong contender in the PsA treatment landscape.
Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic
Original title: “UCB reports positive outcomes for bimekizumab in psoriatic arthritis”